<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Han, Bing</style></author><author><style face="normal" font="default" size="100%">Xu, Ruihua</style></author><author><style face="normal" font="default" size="100%">Shi, Yanxia</style></author><author><style face="normal" font="default" size="100%">Luo, Huiyan</style></author><author><style face="normal" font="default" size="100%">Xiang, Xiaojuan</style></author><author><style face="normal" font="default" size="100%">Li, Yuhong</style></author><author><style face="normal" font="default" size="100%">Zhang, Li</style></author><author><style face="normal" font="default" size="100%">Lin, Tongyu</style></author><author><style face="normal" font="default" size="100%">He, Youjian</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">397-400</style></pages><doi><style  face="normal" font="default" size="100%">10.1007/s11805-007-0397-9</style></doi><volume><style face="normal" font="default" size="100%">4</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">OBJECTIVE To investigate the efficiency and safety of the oxaliplatin, fluorouracil (5-FU) and leucovorin regimen (FOLFOX) in previously untreated patients with metastatic or recurrent colorectal cancer.METHODS Previously untreated patients with metastatic or recurrent colorectal cancer received 100 mg/m2 of oxaliplatin intravenously (IV) over 2 h on day 1, and IV 400 mg/m2 of leucovorin over 2 h followed by a bolus of 400 mg/m2 of 5-FU. Then 2,600~3,000 mg/m2 of 5-FU was administered by continuous infusion over 46 h.RESULTS An evaluated response rate was determined for 97 of 105 treated patients. The overall response rate was 35.1%, 9 patients (9.3%) had a complete response and 25 patients (25.8%) a partial response. Thirtytwo patients (33.0%) developed stable disease and 32.0% of the patients progressed. The median time to progression (TTP) was 7.7 months and the median overall survival 20.5 months. One and 2-year survival rates were 68% and 32%. Toxic effects based on the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), reaching grade 3/4 were: neutropenia 12.3%, anemia 11.3%, vomiting 4.1% and diarrhea 7.2%. Grade 3 neuropathy was 5.1%. The overall survival rate of patients who had received a radical resection was superior to the patients who had not received a operation, or had received a palliative resection (P=0.0658). The serum levels of CEA, ALP and LDH had no relationship with survival (P&gt;0.05).CONCLUSION The FOLFOX regimen containing oxaliplatin, 5-FU plus leucovorin was an efficacious regimen with good tolerability in previously untreated metastatic or recurrent colorectal cancer patients.</style></abstract></record></records></xml>